Glenmark Pharma rises 1% on USFDA nod for Aprepitant capsules
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Aprepitant Capsules USP 40 mg, 80 mg, and 125 mg.
Moneycontrol News
Shares of Glenmark Pharma added 1 percent intraday Monday as it has received approval for Aprepitant Capsules.
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Aprepitant Capsules USP 40 mg, 80 mg, and 125 mg.
Aprepitant Capsules USP is a generic version of Emend Capsules, 40 mg, 80 mg, and 125 mg, of Merck Sharp & Dohme Corporation.
As per IMS Health sales data for the 12 month period ending August 2017, the Emend Capsules achieved annual sales of approximately USD 64.9 million.
The company's current portfolio consists of 127 products authorized for distribution in the US marketplace and 60 ANDA’s pending approval with the USFDA.
In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
The share has declined 32 percent in the last six months.
At 09:21 hrs Glenmark Pharma was quoting at Rs 606.15, up Rs 2.95, or 0.49 percent on the BSE.
Posted by Rakesh Patil
